Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability. The designs described in the application result in the injector performing the reconstitution of the dry drugs into an injectable liquid form and then perform the injection similar to the Antares VIBEX® and QuickShot™ devices. Adding the reconstitution mechanism to the base of the VIBEX® and QuickShot™ injection platform allows the Company to build on its comprehensive technology platform upon which OTREXUP™ was developed. The expiry date for the patent issued in August of 2012 is 2028.
Paul K. Wotton Ph.D., President and CEO commented, "This new patent application confirms our position as a leading developer of drug device combination products and enhances our ability to apply proprietary technology to the new biological generation of drugs which is extremely important for our long term business goals and creation of shareholder value. We are developing a pipeline of injectable products, designed for use in a home care setting and we have extended our intellectual property to reconstitutable drugs, including those biological agents where high viscosity may be a challenge for device technologies less innovative than our VIBEX® or QuickShot™ systems."
Diabetes drugs may reduce risk of opioid overdose and alcohol intoxication